Scientists studied the m6A RNA modification finding that it is pivotal in TDP-43-related neurodegeneration in ALS.
A study published in Molecular Cell suggests that a common modification to RNA plays a pivotal role in TDP-43-related neurodegeneration in ALS.
Nearly 100% of cases of amyotrophic lateral sclerosis—the progressive, fatal neurodegenerative disease known as ALS or Lou Gehrig’s disease — involve the buildup of a protein called TDP-43.
Scientists know that TDP-43, which helps regulate the processing of RNA, may be responsible for the death of nerve cells in ALS and frontotemporal dementia. Previous studies by investigators at Michigan Medicine found that too much TDP-43 in the cells of patients caused the RNA to become very unstable.
Researchers at Michigan Medicine focused on the most abundant RNA modification, a methylation event known as m6A. Through sequencing analysis, investigators showed that methylation strongly influences the binding of TDP-43 to its RNA targets. They also observed highly abundant RNA methylation in the end-stage tissues of patients with ALS.
“This is an RNA modification that has escaped our attention in the past, and yet it is rampant in patients with ALS,” said Sami Barmada, MD, PhD, senior author and Angela Dobson Welch and Lyndon Welch Research Professor of Neurology at the University of Michigan Medical School.
“Despite the fact that we see all this RNA methylation, it’s hard to say exactly what it means,” said Barmada. “It’s like watching the end of the movie and then trying to work out the plot. We see RNA methylation, TDP-43 buildup, and loss of brain cells, but how are these connected?”
Previous studies suggest that total levels of m6A in the nervous system rise with age and that (some) neurodegenerative diseases are characterized by RNA hypermethylation. Significantly, RNA methylation is modified by environmental exposure.
Its presence in ALS, Barmada says, opens up a wide range of possibilities for research of a disease intimately linked to environmental exposure, as demonstrated by Stephen Goutman, MD, MS, and Eva Feldman, MD, PhD, at Michigan Medicine.
Funding was provided by the NIH/NINDS, NIH/NIA, the family of Angela Dobson Welch and Lyndon Welch, the Robert Packard Center for ALS Research, and the Alfred A. Taubman Medical Research Institute.
Barmada is a member of the Scientific Advisory Board for the Robert Packard Center for ALS Research.